Collegium Pharmaceutical Inc. Common Stock (COLL)
Stock · NASDAQ · Health Care
$23.2as of 10/16/2026
Price chart
Active signals
COLL Signal Track Record
How signals performed across all stocks →What COLL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +3.1% | 54% | September 18, 2026 |
| Bollinger Band Breakout | 24 | +5.5% | 63% | July 6, 2026 |
| Bollinger Band Breakdown | 20 | +2.0% | 55% | August 6, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -4.3% | 35% | May 7, 2026 |
| Any 20-session window (baseline) | +0.3% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 423
- Website
- www.collegiumpharma.com/
Fundamentals
- 1-day range
- $22.86$23.41
- Market cap
- $944.15M
- P/E (trailing)
- 15.77
- P/E (forward)
- 3.20
- EPS (trailing)
- $1.11
- Dividend yield
- —
- Beta
- 0.75
- Avg. volume
- 777.3K
How Collegium Pharmaceutical Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Collegium Pharmaceutical Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- COLLCollegium Pharmaceutical Inc. Common Stock$23.19▲ 0.04%Market cap $944.15MP/E 15.77$21.43$50.79
- OMEROmeros Corporation Common Stock$16.2▼ 13.78%Market cap $951.74MP/E 10.87$4.06$21.24
- ANNXAnnexon Inc. Common Stock$3.41▼ 5.28%Market cap $917.52MP/E —$2.54$7.18
- JANXJanux Therapeutics Inc. Common Stock$16.51▼ 4.68%Market cap $981.85MP/E —$12.12$35.34
- OPKOPKO Health Inc. Common Stock$1.53▼ 4.97%Market cap $985.15MP/E —$0.98$1.75
- AVTXAvalo Therapeutics Inc. Common Stock$11.27▼ 6.16%Market cap $989.29MP/E —$12.51$24.27
- ABUSArbutus Biopharma Corporation Common Stock$4.22▼ 1.63%Market cap $896.82MP/E 5.55$3.5$5.45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| COLL Collegium Pharmaceutical Inc. Common Stock | $944.15M | 15.77 | $23.19 | ▲ 0.04% | $21.43$50.79 |
| OMER Omeros Corporation Common Stock | $951.74M | 10.87 | $16.2 | ▼ 13.78% | $4.06$21.24 |
| ANNX Annexon Inc. Common Stock | $917.52M | — | $3.41 | ▼ 5.28% | $2.54$7.18 |
| JANX Janux Therapeutics Inc. Common Stock | $981.85M | — | $16.51 | ▼ 4.68% | $12.12$35.34 |
| OPK OPKO Health Inc. Common Stock | $985.15M | — | $1.53 | ▼ 4.97% | $0.98$1.75 |
| AVTX Avalo Therapeutics Inc. Common Stock | $989.29M | — | $11.27 | ▼ 6.16% | $12.51$24.27 |
| ABUS Arbutus Biopharma Corporation Common Stock | $896.82M | 5.55 | $4.22 | ▼ 1.63% | $3.5$5.45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer SaysYahoo · 10/9/2026
- New Strong Sell Stocks for October 7thYahoo · 10/7/2026
- Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday LifeYahoo · 10/6/2026
- Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · 10/5/2026
- 3 Healthcare Stocks That Concern UsYahoo · 9/30/2026
- 3 Value Stocks That Fall ShortYahoo · 9/28/2026
- Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50Benzinga · 9/23/2026
- 1 Oversold Stock Ready to Bounce Back and 2 We Find RiskyYahoo · 9/22/2026
Insider Activity
Insider Actions →- Gino Santini · June 8, 2026 · Option Exercise8.7K @ $16.49
- John Gordon Freund · May 18, 2026 · Sale20 @ $34.05
- John Gordon Freund · May 15, 2026 · Option Exercise8.7K @ $16.49
- John Gordon Freund · May 15, 2026 · Sale4.1K @ $34.54
- Donovan Michael Glancy · May 14, 2026 · Grant17.5K
- Rita J. Balice-Gordon · May 14, 2026 · Grant8.7K
- Carlos Paya V · May 14, 2026 · Grant8.7K
- Nancy Lurker · May 14, 2026 · Grant8.7K
- John Gordon Freund · May 14, 2026 · Grant8.7K
- Gino Santini · May 14, 2026 · Grant8.7K
- Garen G. Bohlin · May 14, 2026 · Grant8.7K
- Nancy Lurker · May 13, 2026 · Sale4.5K @ $35.97
- Garen G. Bohlin · May 11, 2026 · Option Exercise8.7K @ $16.49
- Garen G. Bohlin · May 11, 2026 · Sale8.7K @ $37.18
Institutional Ownership
March 31, 2026
- Total shares held
- 36.63M
- Total value held
- $1.19B
- Institutional holders
- 258
- Unknown5.13M
- Unknown1.83M
- Unknown1.59M
- Unknown1.50M
- Unknown1.47M
- Unknown1.42M
- Unknown1.42M
- Unknown1.37M
- Unknown1.33M
- Unknown1.30M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer
Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.